Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients

Background: Early detection of white matter lesions in childhood-onset cerebral adrenoleukodystrophy (ALD) is important as hematopoietic cell transplantation (HCT), currently the only effective treatment, is beneficial only if performed early in the disease course. Objective: To establish reliable biochemical markers of cerebral disease progression in patients with ALD to aid in treatment planning. Methods: The authors used proton magnetic resonance spectroscopy (MRS) in combination with LCModel analysis to quantify brain metabolites in small volumes (3 to 16 mL) in the occipital and frontal white matter and the splenium of the corpus callosum of 17 unsedated patients and 26 healthy volunteers (adult n = 21, age-matched n = 5) at 4 tesla. Results: Absolute concentrations of 12 metabolites were reliably determined, seven of which were established as markers of lesion development. Among these, creatine and choline containing compounds were the weakest markers while N-acetylaspartate, glutamine, and lipids + lactate were the strongest. The large extent of changes in the markers enabled detection of early neurochemical changes in lesion formation prior to detection of abnormalities by conventional MRI. Concentrations of a number of metabolites were also significantly different between normal appearing white matter of patients and controls indicating biochemical alterations in the absence of cerebral disease. Neurochemical improvements following HCT were measured in six patients. Conclusions: The progression of adrenoleukodystrophy, as well as effectiveness of its treatment, can be assessed with high precision using high field 1H magnetic resonance spectroscopy in individual patients without the need for sedation.

[1]  P. Molinoff,et al.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .

[2]  J. Strain,et al.  MRI-compatible audio/visual system: impact on pediatric sedation , 2001, Pediatric Radiology.

[3]  Jullie W Pan,et al.  High frequency volume coils for clinical NMR imaging and spectroscopy , 1994, Magnetic resonance in medicine.

[4]  H. Moser,et al.  Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy , 2002, Neurology.

[5]  Roland Kreis,et al.  Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy , 1993, Magnetic resonance in medicine.

[6]  V. Govindaraju,et al.  Proton NMR chemical shifts and coupling constants for brain metabolites , 2000, NMR in biomedicine.

[7]  Stephen K Fisher,et al.  Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance , 2002, Journal of neurochemistry.

[8]  J. Finsterbusch,et al.  Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. , 2003, Neuropediatrics.

[9]  H. Moser,et al.  Adrenoleukodystrophy: a scoring method for brain MR observations. , 1994, AJNR. American journal of neuroradiology.

[10]  U. Mödder,et al.  The value of new MRI techniques in adrenoleukodystrophy , 1997, Pediatric Radiology.

[11]  Der,et al.  Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain. , 1990, Radiology.

[12]  S J Nelson,et al.  Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy. , 1993, Radiology.

[13]  J. Mandel,et al.  Adrénoleucodystrophie liée à l'X , 2007 .

[14]  J. Frahm,et al.  Quantitative Proton Magnetic Resonance Spectroscopy of Childhood Adrenoleukodystrophy , 1998, Neuropediatrics.

[15]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[16]  H. Moser,et al.  X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients , 2000, Neuropediatrics.

[17]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[18]  J. Vion-Dury,et al.  Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy , 1995, Neuroradiology.

[19]  J. Chaussain,et al.  MRI detects cerebral involvement in neurologically asymptomatic patients with adrenoleukodystrophy , 1989, Neurology.

[20]  H. Moser,et al.  Improved tissue characterization in adrenoleukodystrophy using magnetization transfer imaging. , 1996, AJR. American journal of roentgenology.

[21]  H. Moser,et al.  Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls , 1999, Annals of neurology.

[22]  Susumu Mori,et al.  Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience. , 2002, Radiology.

[23]  R Gruetter,et al.  Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. , 1999, Journal of magnetic resonance.

[24]  R. Gruetter,et al.  In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time , 1999, Magnetic resonance in medicine.

[25]  H. Moser,et al.  Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening , 2001, Annals of neurology.

[26]  W. Krivit,et al.  Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. , 1999, Current opinion in neurology.

[27]  D. Leibfritz,et al.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. , 1993, Developmental neuroscience.

[28]  A E Stillman,et al.  Proton MR spectroscopy of childhood adrenoleukodystrophy. , 1996, AJNR. American journal of neuroradiology.

[29]  H. Moser,et al.  X-linked adrenoleukodystrophy: the role of contrast-enhanced MR imaging in predicting disease progression. , 2000, AJNR. American journal of neuroradiology.

[30]  Jens Frahm,et al.  Regional Age Dependence of Human Brain Metabolites from Infancy to Adulthood as Detected by Quantitative Localized Proton MRS , 1999, Pediatric Research.

[31]  H. Moser,et al.  Multislice proton magnetic resonance spectroscopic imaging in X‐linked adrenoleukodystrophy , 1994, Annals of neurology.

[32]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .

[33]  H. Moser,et al.  Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. , 1994, AJNR. American journal of neuroradiology.

[34]  G. Pohost,et al.  Structural studies of NMR detected lipids in myocardial ischemia , 1994, NMR in biomedicine.

[35]  Wolfgang Grodd,et al.  Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases , 2003, Magnetic resonance in medicine.

[36]  H. Moser,et al.  X-linked adrenoleukodystrophy , 1993, Clinical Neurology and Neurosurgery.

[37]  R Gruetter,et al.  Field mapping without reference scan using asymmetric echo‐planar techniques , 2000, Magnetic resonance in medicine.

[38]  I. Jambaqué,et al.  Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy , 2000, The Lancet.